Clinical trial · Interventional
Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma
Multicenter, Open-labeled, Controlled Phase II Study: Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Treatment options for advanced hepatocellular carcinoma (HCC) are limited due to patients' poor condition, advanced tumor, concomitant intra- and extra-liver diseases, and resistance to both chemo- and radio-therapy. Trans-catheter embolization (TAE) or Trans-catheter chemo-embolization (TACE) is the most widely used locoregional treatment for advanced HCC. But no solid evidences support the beneficial effect of the chemotherapy in TACE. Many advanced HCC patients also can't tolerate the locoregional chemotherapy. The p53 gene has multiple anticancer functions and does not have any of the immune-inhibitory effects of chemo- or radio-therapy. The objectives of this study are to investigate the efficacy and safety usingTAE plus recombinant adenoviral human p53 gene (rAd-p53) in treatment of advanced HCC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Adult Hepatocellular Carcinoma | Adult Hepatocellular Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TACE | Drug | — | UNRESOLVED |
| TACE plus rAd-p53 artery injection | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- TACE plus rAd-p53
- description
- TACE plus rAd-p53 artery injection'
- interventionNames
- Drug: TACE plus rAd-p53 artery injection
- type
- ACTIVE_COMPARATOR
- label
- TACE
- description
- TACE will be applied alone
- interventionNames
- Drug: TACE
Primary outcomes (1)
- measure
- overall survival
- timeFrame
- tumor assessment will be performed every 6 weeks from starting study treatment to death or 2 years later
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. histopathologically diagnosed HCC; 2. unresectable; 3. over 18 years old; 4. with an Eastern Cooperative Oncology Group (ECOG) score of 0-2; 5. with Barcelona Clinic Liver Cancer (BCLC) Stage of B or C; 6. with Child-Pugh score A or B; 7. with normal tests of hemogram, blood coagulation, liver and kidney function; 8. signed the informed consent form. Exclusion Criteria: 1. Serious blood coagulation disorder, bleeding tendency, platelet \< 6 \* 1000000000/L; 2. have serious heart, lung function abnormalities or severe diabetes patients; 3. active infection; 4. liver function Child-Pugh grade C; 5. secondary and diffuse hepatocellular carcinoma patients; 6. extensive metastasis; 7. severe atherosclerosis; 8. AIDS patients; 9. serious thrombotic or embolic events within 6 months; 10. renal insufficiency requiring hemodialysis or peritoneal dialysis; 12\. pregnant or lactating women; 13\. mental disorder or disease.
References
Publications (0)
Data not yet available